Accession Number:

AD1040554

Title:

Annual Surveillance Summary: Vancomycin-Resistant Enterococci (VRE) Infections in the Military Health System (MHS), 2016

Descriptive Note:

Technical Report,01 Jan 2016,31 Dec 2016

Corporate Author:

NAVY AND MARINE CORPS PUBLIC HEALTH CENTER PORTSMOUTH VA PORTSMOUTH

Personal Author(s):

Report Date:

2017-06-01

Pagination or Media Count:

21.0

Abstract:

The EpiData Center Department EDC conducts routine surveillance of vancomycin-resistant enterococci VRE incidence and prevalence among all beneficiaries seeking care within the Military Health System MHS. This report describes demographics, clinical characteristics, prescription practices, and antibiotic resistance patterns observed for VRE in calendar year CY 2016. Multiple data sources were linked to assess descriptive and clinical factors related to VRE. Health Level 7 HL7-formatted Composite Health Care System CHCS microbiology data identified Enterococcus species infections with vancomycin resistance. These infections were matched to HL7-formatted CHCS pharmacy data to assess prescription practices, the Standard Inpatient Data Record SIDR to determine healthcare-associated exposures, Defense Manpower Data Center DMDC rosters to determine burden among Department of Defense DOD active duty AD service members, and the DMDC Contingency Tracking System CTS to determine Department of the Navy DON deployment-related infections. In 2016, VRE infection rates declined among MHS beneficiaries to 1.38 per 100,000 persons per year, following a three-year incline from 2013-2015. The United States US West and South regions had the highest rates, and healthcare-associated HA cases comprised the largest proportion of all infections identified 87 . While the majority of all prevalent infections were classified as hospital-onset HO 45 , a substantial proportion was also identified as community-onset CO 31 . Treatment for VRE infections among DOD beneficiaries primarily included daptomycin and linezolid, which remained effective throughout 2016. These findings warrant continued surveillance to understand the evolving impact of VRE within the MHS.

Subject Categories:

  • Microbiology
  • Pharmacology
  • Military Forces and Organizations

Distribution Statement:

APPROVED FOR PUBLIC RELEASE